[CAS NO. 379270-37-8] Tenofoviralafenamide

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [379270-37-8]

Catalog

HY-15232

Brand

MCE

CAS

379270-37-8

DESCRIPTION [379270-37-8]

Overview

MDL	MFCD23843796
Molecular Weight	476.47
Molecular Formula	C21H29N6O5P
SMILES	NC1=NC=NC2=C1N=CN2C[C@@H](C)OC[P@](OC3=CC=CC=C3)(N[C@@H](C)C(OC(C)C)=O)=O

For research use only. We do not sell to patients.

5 Publications Citing Use of MCE

Summary

Tenofovir alafenamide (GS-7340) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor .

IC50 & Target

HIV-1

HIV-2

In Vitro

Tenofovir alafenamide (GS-7340) antiviral activities are similar across all cell types, ranging from 5 to 7 nM, while the CC ₅₀ varies from 4.7 to 42 μM for MT-4 and MT-2 cells, respectively. The antiviral activity of TAF is evaluated against a panel of HIV-1 and HIV-2 isolates, including HIV-1 group M subtypes A to G, as well as group N and O isolates. Overall, for the 29 primary HIV-1 isolates tested in PBMCs, TAF EC ₅₀ s range from 0.1 to 12 nM, with a mean EC ₅₀ of 3.5 nM compared to a mean EC ₅₀ of 11.8 nM for AZT, which is used as an internal control. For the HIV-2 isolates, the mean EC ₅₀ s are 1.8 nM for TAF and 6.4 nM for AZT ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tenofovir alafenamide (GS-7340) hemifumarate is an amidate prodrug of Tenofovir with good oral bioavailability and increases plasma stability compared to Tenofovir disoproxil fumarate (TDF) ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04391608	Mahidol University	Renal Insufficiency\|Tenofovir	November 9, 2019	Phase 4
NCT04034368	The First Hospital of Jilin University	HBV	August 2019	Phase 4
NCT04891770	Gilead Sciences\|Vir Biotechnology, Inc.	Chronic Hepatitis B	August 14, 2021	Phase 2
NCT05404919	University of Pennsylvania	Lung Transplant\|Hepatitis B	September 6, 2022	Phase 2
NCT04211805	New Discovery LLC	Hepatitis B, Chronic\|Pregnancy Related	January 27, 2020
NCT03887702	Southwest Oncology Group\|National Cancer Institute (NCI)	Hepatitis B Infection\|Malignant Solid Neoplasm	February 21, 2019	Phase 3
NCT02904369	CONRAD\|United States Agency for International Development (USAID)\|Agility Clinical, Inc.	HIV	October 6, 2016	Phase 1
NCT03604016	IlDong Pharmaceutical Co Ltd	Hepatitis B	September 23, 2018	Phase 4
NCT05583006	Taichung Veterans General Hospital	Patient Satisfaction\|Drug Adherence\|Efficacy, Self\|Safety Issues	December 1, 2022
NCT02357602	University of North Carolina, Chapel Hill\|Gilead Sciences	Healthy	March 2015	Phase 1
NCT03549689	Philip Grant\|Stanford University	HIV+AIDS\|HIV-1-infection\|Osteopenia	August 1, 2019	Phase 2
NCT04196998	Third Affiliated Hospital, Sun Yat-Sen University	Hepatitis B\|Compensated Cirrhosis	January 1, 2019	Not Applicable
NCT04535544	Janssen Research & Development, LLC	Hepatitis D, Chronic	September 17, 2020	Phase 2
NCT04619082	Chiayi Christian Hospital\|St. Martin De Porress Hospital\|Dalin Tzu Chi General Hospital\|National Taiwan University Hospital, Yun-Lin Branch\|Chi Mei Medical Hospital	Hepatitis B Reactivation	July 1, 2021	Phase 4
NCT05063071	Fudan University	HBV\|POST LIVER TRANSPLANT	July 29, 2021	Phase 4
NCT05453448	Xiangya Hospital of Central South University	Antiviral Drugs	May 1, 2022	Not Applicable
NCT05423834	Chinese University of Hong Kong	Chronic Hepatitis B	August 1, 2022
NCT03646370	Thomas Jefferson University	HIV-1-infection\|Metabolic Syndrome\|Cardiovascular Diseases\|Weight Gain\|Renal Function Abnormal\|Hyperglycemia	July 25, 2018
NCT03115736	University Hospital Inselspital, Berne	HIV and Hepatitis B Coinfection	May 23, 2017	Phase 2
NCT04070079	University Health Network, Toronto	Hepatitis B, Chronic	January 29, 2019	Phase 4
NCT05410496	Taichung Veterans General Hospital	Safety Issues	June 22, 2021	Phase 4
NCT04997564	Peking University First Hospital	Chronic Hepatitis C\|Chronic Hepatitis B	August 2021	Phase 4
NCT04864366	Huashan Hospital	Chronic Hepatitis B	April 30, 2021
NCT05001672	Taipei Veterans General Hospital, Taiwan	HBV\|Inflammatory Arthritis	August 15, 2021	Phase 4
NCT02957994	Asian Pacific Liver Center at Coalition of Inclusive Medicine	Hepatitis B	December 22, 2016	Phase 4
NCT04518228	National Institute of Allergy and Infectious Diseases (NIAID)\|International Maternal Pediatric Adolescent AIDS Clinical Trials Group\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|National Institute of Mental Health (NIMH)\|Gilead Sciences\|ViiV Healthcare\|Merck Sharp & Dohme LLC	HIV Infections\|Tuberculosis	June 8, 2021
NCT03489239	Thomas Jefferson University\|Gilead Sciences	Hepatitis B	November 16, 2017	Phase 3
NCT05550519	Janssen Pharmaceutica N.V., Belgium	Hepatitis B, Chronic	October 31, 2022	Early Phase 1
NCT03804372	Gruppo Italiano Malattie EMatologiche dell´Adulto	Large-B-cell Diffuse Lymphoma\|Chronic Lymphoid Leukemia	July 7, 2020	Phase 2
NCT03566030	Yonsei University	Hepatitis B\|Antiviral Drug Adverse Reaction	September 1, 2018
NCT02984852	Janssen Scientific Affairs, LLC	Healthy	December 2016	Phase 1
NCT04129554	Janssen Sciences Ireland UC	Hepatitis B, Chronic	November 6, 2019	Phase 2
NCT04195074	Third Affiliated Hospital, Sun Yat-Sen University	Chronic Hepatitis b	January 1, 2019	Not Applicable
NCT04712058	National Taiwan University Hospital\|Far Eastern Memorial Hospital\|Mackay Memorial Hospital\|Changhua Christian Hospital\|Chung Shan Medical University\|National Cheng-Kung University Hospital\|Chi Mei Medical Hospital\|Kaohsiung Medical University Chung-Ho Memorial Hospital\|Kaohsiung Municipal Ta-Tung Hospital	HIV Infections	January 20, 2021	Not Applicable
NCT04674423	National Cheng-Kung University Hospital	Chronic Hepatitis b	May 14, 2020	Phase 4
NCT04667104	Janssen Research & Development, LLC	Hepatitis B, Chronic	February 1, 2021	Phase 2
NCT03356834	Humanity and Health Research Centre	Chronic Hepatitis B	December 1, 2017	Phase 4
NCT03752658	Tongji Hospital\|Gilead Sciences	Chronic Hepatitis b	January 25, 2019
NCT03559790	The Catholic University of Korea	Chronic Hepatitis b	July 18, 2018
NCT04937881	University of California, Los Angeles\|University of Cape Town\|Desmond Tutu HIV Foundation\|Gilead Sciences	Hiv	June 13, 2022	Phase 3
NCT03122262	Professor Francois Venter\|University of Witwatersrand, South Africa	HIV-1 Infection	January 16, 2017	Phase 3
NCT04850950	The First Affiliated Hospital of Zhengzhou University\|National Natural Science Foundation of China\|Henan Provincial People´s Hospital\|The Sixth People´s Hospital of Zhengzhou\|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School\|Second Affiliated Hospital of Xi´an Jiaotong University\|Shandong Provincial Hospital\|Luoyang Central Hospital\|First Affiliated Hospital of Nanyang Medical College\|Sixth People´s Hospital of Kaifeng\|Luohe Central Hospital\|Xinyang Central Hospital\|Yan´an University Affiliated Hospital\|Nanyang Central Hospital\|Fifth People´s Hospital of Anyang	Chronic Hepatitis B\|Mother-to-Child Transmission\|Safety\|Efficacy\|Hepatitis B Virus\|Tenofovir Alafenamide Fumarate	April 26, 2021	Phase 4
NCT00036634	Gilead Sciences	HIV Infections	March 2002	Phase 1\|Phase 2
NCT04483674	Anna Cruceta\|Fundacion Clinic per a la Recerca Biomédica	HIV Primary Infection	December 4, 2020	Phase 2
NCT01671787	Gilead Sciences	Chronic Hepatitis B	March 2012	Phase 1
NCT04629976	Nucorion Pharmaceuticals, Inc.\|Ligand Pharmaceuticals	Chronic Hepatitis B	January 12, 2021	Phase 1
NCT04201808	New Discovery LLC\|Beijing Ditan Hospital	Hepatitis B, Chronic	May 1, 2021	Phase 4
NCT04616963	University of California, San Diego	Hiv\|Hormone Therapy	October 24, 2019	Phase 4
NCT03920618	Third Affiliated Hospital, Sun Yat-Sen University	Hepatitis B\|Acute-On-Chronic Liver Failure	February 1, 2019	Not Applicable
NCT04703465	RenJi Hospital	HBV\|Liver Transplant Disorder	April 1, 2021	Not Applicable
NCT04585789	Janssen Research & Development, LLC	Hepatitis B	March 11, 2021	Phase 2
NCT03753074	Young-Suk Lim\|Samsung Medical Center\|Kyunghee University Medical Center\|Chung-Ang University Hosptial, Chung-Ang University College of Medicine\|Seoul National University Hospital\|Ulsan University Hospital\|Konkuk University Medical Center\|Kyungpook National University Hospital\|Korea University Guro Hospital\|Seoul St. Mary´s Hospital\|Kaohsiung Medical University\|Chang Gung Memorial Hospital\|E-DA Hospital\|Taitung Mackay Memorial Hospital\|National Cheng-Kung University Hospital\|Chi Mei Medical Hospital\|Chiayi Christian Hospital\|St. Martin De Porress Hospital\|Dalin Tzu Chi General Hospital\|Taichung Veterans General Hospital\|China Medical University Hospital\|Asan Medical Center	Chronic Hepatitis b	February 18, 2019	Phase 4
NCT04237376	New Discovery LLC	Hepatitis B, Chronic\|Pregnancy Related	April 9, 2019
NCT03695029	National Taiwan University Hospital	Hepatitis B Virus Infection	December 29, 2010	Phase 4
NCT04880577	Massachusetts General Hospital\|Gilead Sciences	Multiple Sclerosis, Relapsing-Remitting\|Fatigue	September 15, 2022	Phase 2
NCT04507607	Third Affiliated Hospital, Sun Yat-Sen University	Chronic Hepatitis B\|Mother-to-child Block\|Antiviral Treatment	August 1, 2020	Early Phase 1
NCT05467553	National Taiwan University Hospital\|PharmaEssentia	Hepatitis D	August 31, 2022	Phase 2
NCT04683341	Kaohsiung Medical University Chung-Ho Memorial Hospital	HBV	September 1, 2020	Phase 4
NCT05423106	Janssen Research & Development, LLC	Healthy\|Hepatitis B, Chronic	July 4, 2022	Phase 1
NCT02957864	Erasmus Medical Center\|Gilead Sciences	Renal Insufficiency,Chronic\|Hiv\|Therapeutic Agent Toxicity	October 2016	Phase 4
NCT03241641	Young-Suk Lim\|Samsung Medical Center\|Korea University Guro Hospital\|Konkuk University Medical Center\|Seoul National University Hospital\|Asan Medical Center	Chronic Hepatitis b	October 26, 2017	Phase 4
NCT03933384	Taichung Veterans General Hospital	Hepatitis B\|Viral Hepatitis	August 19, 2019	Phase 4
NCT04059198	F-star Therapeutics, Inc.\|PRA Health Sciences	Hepatitis B\|HBV\|Hepatitis B, Chronic	October 10, 2019	Phase 2
NCT03640728	First Affiliated Hospital Xi´an Jiaotong University	Hepatitis B\|Virus Diseases\|Liver Failure	January 25, 2019
NCT04939441	Jidong Jia\|Beijing Ditan Hospital\|ShuGuang Hospital\|Tianjin Third Central Hospital\|Huashan Hospital\|The Sixth Peoples Hospital of Zhengzhou\|Tianjin Second People´s Hospital\|Ruijin Hospital\|Shanghai East Hospital\|Beijing Friendship Hospital	Chronic Hepatitis B	April 20, 2021	Phase 4
NCT05177926	Nanfang Hospital of Southern Medical University\|Gilead Sciences\|Tigermed Consulting Co., Ltd	Hepatitis B, Chronic\|Mother to Child Transmission	April 4, 2021	Phase 4
NCT04065230	Southeast University, China	Hepatitis B Virus\|Mother to Child Transmission	August 2019
NCT03471624	Stanford University\|Gilead Sciences	Hepatitis B, Chronic	May 1, 2018	Phase 4
NCT04054089	Cristina Mussini\|University of Modena and Reggio Emilia	HIV Infections	September 2019	Phase 4
NCT04585737	Charlotte-Paige Rolle, MD\|ViiV Healthcare\|Orlando Immunology Center	HIV I Infection	September 22, 2020	Phase 4
NCT04231565	Third Affiliated Hospital, Sun Yat-Sen University	Hepatitis B Virus	January 31, 2021	Not Applicable
NCT02995252	University of Maryland, Baltimore	Hepatitis B? Chronic\|Hepatitis C	December 2014
NCT05275023	Janssen Research & Development, LLC	Hepatitis B, Chronic	June 30, 2022	Phase 2
NCT02437110	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	Amyotrophic Lateral Sclerosis	April 1, 2019	Phase 1
NCT04439539	Janssen Research & Development, LLC	Hepatitis B, Chronic	September 14, 2020	Phase 2
NCT03798119	Kaohsiung Medical University Chung-Ho Memorial Hospital	Hepatitis B\|Fibrosis and Cirrhosis of Liver	February 25, 2019	Phase 4
NCT05244057	Shanghai HEP Pharmaceutical Co., Ltd.\|Shanghai Tong Ren Hospital\|Shanghai East Hospital	Chronic Hepatitis B	February 2022	Phase 2
NCT04501224	Third Affiliated Hospital, Sun Yat-Sen University	Chronic Hepatitis b\|Cirrhosis Due to Hepatitis B	August 3, 2020	Not Applicable
NCT00042289	National Institute of Allergy and Infectious Diseases (NIAID)\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	HIV Infections	June 9, 2003
NCT05195450	Institute of Liver and Biliary Sciences, India	Non-cirrhotic, Chronic Hepatitis B	February 23, 2022	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 31 mg/mL ( 65.06 mM )

H ₂ O : 6.67 mg/mL ( 14.00 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0988 mL	10.4938 mL	20.9877 mL
5 mM	0.4198 mL	2.0988 mL	4.1975 mL
10 mM	0.2099 mL	1.0494 mL	2.0988 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 40 mg/mL (83.95 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (4.37 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (4.37 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (4.37 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

L-Alanine, N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester

GS 7340

Tenofovir alafenamide

4: PN: WO2016077321 SEQID: 4 claimed sequence

Vemlidy